Scott Tagawa, MD, MS, FACP, Professor of Medicine and Urology at Weill Cornell Medicine, and an Attending Physician at New York-Presbyterian – Weill Cornell Medical Center, shares what needs to happen for radionuclide therapies to make their way into the community setting. How can community oncologists and urologists prepare themselves to offer these therapies?
View Dr. Tagawa’s other comments on prostate cancer management, including PSMA PET Versus Cross-Sectional Imaging and Appropriate and Potential Off-Label Utility of Lutetium-177–PSMA-617.